{
    "clinical_study": {
        "@rank": "50456", 
        "acronym": "SPIRE-SI", 
        "arm_group": [
            {
                "arm_group_label": "PF-04950615", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Atorvastatin", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a multicenter, double blinded, active and placebo controlled randomized\n      clinical trial to demonstrate a superior lipid lowering effect of RN316 (PF-04950615)\n      compared to placebo in subjects who are statin intolerant."
        }, 
        "brief_title": "Randomized Clinical Trial of RN316 (PF-04950615) in Subjects Who Are Intolerant to Statins", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperlipidemia", 
        "condition_browse": {
            "mesh_term": "Hyperlipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hyperlipidemia\n\n          -  Statin Intolerant\n\n          -  Fasting LDL-C > + 70 mg/dL Fasting TG < = 400 mg/dL\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding females\n\n          -  Cardiovascular or cerebrovascular event or procedure within 90 days\n\n          -  Severe or life-threatening adverse events with past use of statins\n\n          -  Poorly controlled hypertension"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02135029", 
            "org_study_id": "B1481030", 
            "secondary_id": "STATIN INTOLERANT"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-04950615", 
                "description": "150 mg every 2 weeks by subcutaneous injection for 24 weeks", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Drug", 
                "other_name": "RN316"
            }, 
            {
                "arm_group_label": "Atorvastatin", 
                "description": "Atorvastatin PO QD", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "150 mg every 2 weeks by subcutaneous injection for 24 weeks", 
                "intervention_name": "Placebo for PF-04950615", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "PO QD", 
                "intervention_name": "Placebo for atorvastatin", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hyperlipidemia", 
            "statin intolerance"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481030&StudyName=Randomized%20Clinical%20Trial%20of%20RN316%20%28PF-04950615%29%20in%20Subjects%20who%20are%20Intolerant%20to%20Statins"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3, Double-blind, Randomized, Placebo and Active Controlled, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of PF-04950615 in Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia Who Are Intolerant to Statin", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Fasting Low Density Lipoprotein Cholesterol (LDL-C)", 
            "measure": "Percentage change from baseline in fasting LDL-C at week 12", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02135029"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percent change in fasting Total Cholesterol (TC), Apolipoprotein B (Apo B), non HDL-C, Lipoprotein (a) (Lp(a), High Density Lipoprotein (HDL), Triglyceride, ApoA-I, and ApoA-II blood concentrations.", 
                "measure": "Change from Baseline in Lipid Parameters at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "description": "Percent change in fasting Total Cholesterol (TC), LDL-C, Apolipoprotein B (Apo B), non HDL-C, Lipoprotein (a) (Lp(a), High Density Lipoprotein (HDL), Triglyceride, ApoA-I, and ApoA-II blood concentrations.", 
                "measure": "Change from Baseline in Lipid Parameters at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24"
            }, 
            {
                "description": "Absolute change in fasting LDL-C, TC, HDL-C, non-HDL-C, TG, ApoB, ApoA-I, ApoA-II, and Lp(a)", 
                "measure": "Change from Baseline in Lipid Parameters at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "description": "Absolute change in fasting LDL-C, TC, HDL-C, non-HDL-C, TG, ApoB, ApoA-I, ApoA-II, and Lp(a)", 
                "measure": "Change from Baseline in Lipid Parameters at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24"
            }, 
            {
                "description": "Proportion of subjects achieving fasting LDL-C less or equal than 100mg/dL", 
                "measure": "Proportion of subjects achieving fasting LDL-C less or equal than 100mg/dL at week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Proportion of subjects achieving fasting LDL-C less or equal than 100mg/dL", 
                "measure": "Proportion of subjects achieving fasting LDL-C less or equal than 100mg/dL at week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Proportion of subjects achieving fasting LDL-C less or equal than 70mg/dL", 
                "measure": "Proportion of subjects achieving fasting LDL-C less or equal than 70mg/dL at week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Proportion of subjects achieving fasting LDL-C less or equal than 70mg/dL", 
                "measure": "Proportion of subjects achieving fasting LDL-C less or equal than 70mg/dL at week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Plasma PF-04950615 concentration", 
                "measure": "Plasma PF-04950615 concentration at week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Plasma PF-04950615 concentration", 
                "measure": "Plasma PF-04950615 concentration at week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "incidence and titer of anti-drug and neutralizing antibodies", 
                "measure": "Antidrug antibodies", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Proportion of subjects discontinuing treatment due to musculoskeletal adverse events", 
                "measure": "Proportion of subjects discontinuing treatment due to musculoskeletal adverse events", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}